echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The first imitation drug competition for the market, within a week 3 approved!

    The first imitation drug competition for the market, within a week 3 approved!

    • Last Update: 2020-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "Pharmaceutical Network Product Information" Recently, Dongsun 4 class of generic drug Liglitin tablets approved by the State Drug Administration for listing, for the first imitation in ChinaIt is understood that liglitin is a DPP-4 inhibitor, the original research by Bollinger Ingham and Lilly jointly developed, is a high-selection DPP-4 inhibitor class oral hypoglycemia, can be used in combination with metformin hydrochloride, on the basis of diet and exercise to improve blood sugar control, for adult type 2 diabetes patients blood sugar controlAs we all know, China is the world's largest number of diabeticpatients, in recent years, with the increase in diabetes patients, the use of diabetes drugs has increased significantlyData show that in 2018, China's public medical institutions terminal diabetes drug sales of 51.228 billion yuan, an increase of 12.79 percent year-on-yearAmong them, sales of non-insulin-type blood glucose drugs amounted to 25.344 billion yuan, up 18.3% yoY, accounting for 49.47% of the diabetes drug marketAs a result, thanks to a large market base, the industry expects that the sales prospects of the East Sunshine 4 generic ligretin tablets will be very impressive after they are releasedHowever, it is worth noting that there are 5 approved DPP-4 inhibitors in ChinaAmong them, Sigretin, Sagretin, Viglitin and Agretin have previously been approved for the market, the future market competition in this field of drugs will be more intenseUniquely, on July 15, Nanjing Hang Seng Pharmaceutical sepsis four generic drugs carbonate Swiram tablets were also approved by the State Drug Administration for listing, the first imitation in ChinaIt is reported that the carbonate diviram tablets are used to control chronic kidney disease (CKD) adult patients who are receiving dialysis treatment of hyperphosphateThe drug was developed by Sanofi and was approved for entry into China in June 2013In 2019, Sanofis Viram had sales of 311 million eurosAt present, the domestic listed end-stage kidney disease dialysis patients with hyperphosphate treatment drugs are mainly sviram and carbonic acidAccording to IQVIA, sales of these two drugs in China will be about 353 million yuan in 2018Among them, the domestic carbonic acid has been the first imitation of Mingrui Pharmaceuticals approvedIn addition, the domestic according to the new 4 categories submitted carbonate Willam film listing application manufacturers also have the first sound pharmaceutical industry and Xuantai Haimen Pharmaceuticals / Anyan PharmaceuticalsDr Reddy's laboratory in India has also previously filed a listing application for the drug under category 5.2 In addition to the two drugs mentioned above, one of the first generic drugs was also approved for the market during the week It is Jiangxi Shanxiang Pharmaceutical s4 class of generic drug Aiomeprazole magnesium intestinal tablets, July 8 it was approved by the State Drug Administration for listing, for the first domestic imitation, approved as if through the consistency evaluation It is understood that Aiomeprazole is a proton pump inhibitor drug, the original study is developed by AstraZeneca Omeprazole S-Isomer, can effectively inhibit the secretion of stomach acid, clinically used to treat gastroesophageal reflux disease, corrosive reflux esophagitis and so on In 2019, aussomeramazole sales of AstraZeneca, its original research company, were $1.483 billion, with domestic sales of about $2.3 billion At present, the domestic market sales of Aiomeprazole, including Aiomeprazole magnesium intestinal tablets, injection with Esomeprazole sodium, Aisomeprazole intestinal capsules According to insight database, the domestic approved Aiomeprazole is mainly injectable, with 28 injection numbers approved; In addition, the domestic development of Aiomeprazole magnesium intestinal tabletmanufacturers also have Haussen Pharmaceuticals, Nanjing Yuke Pharmaceuticals and Shuanghe Pharmaceuticals, the future market competition in the drug is expected to be very fierce In recent years, China's generic drug market continues to change In addition to the "first-in-class imitation", for generic supping enterprises, whether to successfully pass the consistency evaluation has also become a further occupation of the market needs to cross the threshold In the future, with the continuous improvement of national collection and consistency evaluation policies, the competition of pharmaceutical companies will be more intense, and generic drug market will also be further "slim." 
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.